[Synergic effect of albendazole plus metronidazole association in the treatment of metronidazole-resistant giardiasis]

Clin Ter. 1995 Dec;146(12):761-7.
[Article in Italian]

Abstract

Twenty patients with intestinal giardiasis, already resistant to 3-5 previous courses of oral metronidazole, were randomly distributed into 2 different groups: 10 subjects were given oral albendazole (440 mg/two times per day for 7 days) and 10 were submitted to the association of albendazole (400 mg/two times per day for 7 days) plus metronidazole (250 mg/three times per day for 7 days). All patients were evaluated both for clinical and parasitological status, immediately before and after therapy and, then, 4 weeks later. Only 3 patients of those treated with albendazole alone, showed a clinical and parasitological remission at the end of therapy, and one of them relapsed 4 weeks later. All patients who underwent albendazolemetronidazole association responded to the therapy and all except one were defined as "cured" 4 weeks later. Our study demonstrates that albendazole alone is not an effective therapeutic alternative for "metronidazole-resistant" giardiasis. The association of metronidazole plus albendazole seems synergic and deserves further studies.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Comparative Study
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Albendazole / therapeutic use*
  • Animals
  • Antiprotozoal Agents / therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Drug Therapy, Combination
  • Female
  • Giardia lamblia / drug effects
  • Giardiasis / drug therapy*
  • Giardiasis / parasitology
  • Humans
  • Male
  • Metronidazole / therapeutic use*

Substances

  • Antiprotozoal Agents
  • Metronidazole
  • Albendazole